PBH

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2006, for Prestige Brands Holdings, Inc. and its indirect wholly-owned subsidiary, Prestige Brands International, LLC. The company markets, sells, and distributes over-the-counter (OTC) drugs, personal care, and household cleaning brands to mass merchandisers, drug stores, and supermarkets primarily in the United States and Canada. The financial information for both registrants is identical as the parent company does not conduct ongoing business operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 19.7% year-over-year. Excluding the impact of the Chore Boy and The Doctor's acquisitions, organic revenue growth was 8.4%.
• Segment Performance:
  • OTC Drugs: Revenues rose 18.6% to $39.6 million, driven by Clear Eyes, Murine, and Compound W.
  • Household Cleaning: Revenues surged 31.9% to $30.1 million, largely due to the Chore Boy acquisition and growth in Comet and Spic and Span.
  • Personal Care: Revenues declined 14.1% to $6.2 million due to weakening trends for Cutex, Denorex, and Prell.
• Profitability: Operating income increased 27.9% to $23.3 million. Net income rose 39.3% to $8.3 million. Gross margin percentage decreased to 52.2% from 54.4% due to higher product, packaging, and transportation costs.
• Expenses: Advertising and promotion expenses decreased 15.0% to $7.4 million. General and administrative expenses increased 31.0% to $6.4 million, primarily due to staffing additions and severance costs.
• Interest Expense: Net interest expense increased 15.1% to $9.8 million due to rising interest rates on variable-rate debt.

Outlook, Risks, and Contingencies

• Acquisitions: The company completed the acquisition of the Chore Boy brand (October 2005) and Dental Concepts, LLC (November 2005), which contributed to revenue growth in the current quarter.
• Legal Proceedings:
  • Securities Class Action: A consolidated putative securities class action lawsuit regarding the company's IPO and accounting disclosures remains pending. The court dismissed claims under the Securities Exchange Act of 1934, but claims under the Securities Act of 1933 remain. Management believes the claims are legally deficient.
  • Similasan Litigation: Similasan Corporation filed a lawsuit alleging trademark infringement and deceptive trade practices regarding Murine products. A cease and desist letter regarding trade secrets was also received. Management intends to vigorously defend these claims.
  • Theodosakis Case: A trade dress infringement lawsuit regarding the ARTHx brand was dismissed on appeal, and a petition for rehearing was denied in June 2006.
• Debt Covenants: The company is in compliance with financial covenants under its Senior Credit Facility and Senior Notes, including leverage, interest coverage, and fixed charge coverage ratios.
• Market Risks: The company faces risks related to interest rate fluctuations on variable-rate debt (mitigated by interest rate caps), concentration of sales among a few customers (one customer represents 25.2% of sales), and reliance on third-party manufacturers.

Investor Verification Checklist

• Customer Concentration: Verify the stability of the relationship with the single customer representing 25.2% of net sales and 21.9% of accounts receivable.
• Personal Care Segment Decline: Assess the long-term viability of the Personal Care segment, which saw a 14.1% revenue drop and significant prior impairment charges.
• Legal Exposure: Monitor the status of the Similasan litigation and the remaining claims in the securities class action lawsuit for potential financial impact.
• Debt Service: Confirm the company's ability to service $490.7 million in debt, particularly given the variable interest rate exposure on the $364.7 million term loan.
• Margin Pressure: Evaluate the sustainability of gross margins given the noted increases in product, packaging, and transportation costs.